| Literature DB >> 25152759 |
Irene Pais1, Nuno Correia2, Isabel Pimentel3, Maria José Teles4, Esmeralda Neves5, Júlia Vasconcelos5, Judite Guimarães5, Nancy Azevedo5, António Moreira Pinto6, Jorge Machado7, Thomas Efferth8, Henry J Greten9.
Abstract
Chemotherapy is one of most significant therapeutic approaches to cancer. Immune system functional state is considered a major prognostic and predictive impact on the success of chemotherapy and it has an important role on patients' psychoemotional state and quality of life. In Chinese medicine, chemotherapy is understood as "toxic cold" that may induce a progressive hypofunctional state of immune system, thus compromising the fast recovery of immunity during chemotherapy. In this study, we performed a standardized acupuncture and moxibustion protocol to enhance immunity in cancer patients undergoing chemotherapy and to assess if the improvement of immunity status correlates with a better psychoemotional state and quality of life.Entities:
Year: 2014 PMID: 25152759 PMCID: PMC4131450 DOI: 10.1155/2014/217397
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1CONSORT flow of participants through the study.
Figure 2Study flow chart. Black solid dots: time points of outcome measurements. Open circle: first chemotherapy day. Black diamonds: the primary endpoints of the study. Dashed lines: the expected changes, during chemotherapy, of white blood cells (WBC) and absolute neutrophil counts (ANC). Short, blue down arrows: acupuncture treatments. CBC, complete blood counts; NK, NK cells and subsets.
Baseline comparison between groups: sociodemographic and clinical characteristics; blood analyses and QOL-CR 29 and HADS scores.
| Characteristics | Experimental group ( | Control group ( |
|---|---|---|
| Age | ||
| Mean; range | 62.2; 38–74 | 56.6; 43–74 |
| Cancer type | ||
| Colon | 8 (88.9%) | 9 (100%) |
| Rectum | 1 (11.1%) | 0 (0%) |
| Tumor staging | ||
| II | 1 (11.1%) | 2 (22.2%) |
| III | 7 (77.8) | 3 (33.3%) |
| IV | 1 (11.1%) | 4 (44.4%) |
| Type of chemotherapy | ||
| FOLFOX | 6 (66.7%) | 6 (66.7%) |
| XELOX | 1 (11.1%) | 2 (22.2%) |
| FOLFIRI | 1 (11.1%) | 0 |
| Capecitabine | 1 (11.1%) | 1 (11.1%) |
| Blood analyses ( |
|
|
| WBC ( | 6367.78; 897.55 | 5915.56; 1288.59 |
| ANC ( | 3128.78; 996.25 | 3219; 1199.07 |
| Total lymphocyte ( | 1734.59; 586.98 | 1842.28; 735.77 |
| B cells ( | 170.88; 51.59 | 169.25; 168.91 |
| T cells ( | 1378.95; 540.62 | 1548.76; 613.11 |
| NK cells ( | 184.52; 81.07 | 123.44; 88.46 |
| QOL-Cr 29 and HADS scores ( |
|
|
| Anxiety ( | 14.78; 6.45 | 15.67; 3.53 |
| Depression ( | 16.11; 5.84 | 14.33; 3.12 |
| Urological symptoms ( | 7.67; 1.00 | 7.89; 0.93 |
| Gastrointestinal symptom ( | 7.67; 2.74 | 8.44; 3.54 |
| Defecation symptoms ( | 6.22; 6.05 | 10.67; 3.67 |
| Stoma-related symptoms ( | 2.89; 4.40 | —a |
| Chemo side effects ( | 8.33; 1.93 | 6.67; 2.06 |
| Male sexual function ( | 3.00; 2.59 | 1.56; 2.40 |
| Female sexual function ( | 0.78; 1.20 | 1.78; 1.56 |
| Weight concerns ( | 2.44; 1.24 | 2.56; 1.33 |
| Body image ( | 4.56; 1.42 | 4.78; 2.49 |
| Future concerns ( | 2.89; 1.36 | 3.33; 0.71 |
(S.d., standard deviation; P < 0.05 considered statistically significant; —a, no patients with stoma bag on the control group.)
Figure 3WBC and ANC. Comparison between groups.
Figure 4Total lymphocytes and T and B cells. Comparison between groups.
Figure 5Total NK cells counts. Comparison between groups.
Figure 6HADS scores. Differences among groups, at beginning (T 0) and at the end (T 3) of the study.
Figure 7Symptoms related to QOL questionnaires. Differences among groups at the beginning (T 0) and at the end (T 3) of the study. CT, control group; AcuMoxa, experimental group.
Figure 8Chemotherapy side effects. Intragroup analyses show significant decrease of chemotherapy side effects among AcuMoxa group.